Skip to main content
Evidence Snapshot

JeKo-1

CHEMBL4296445 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T12:56:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296445
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats JeKo-1 as ChEMBL target CHEMBL4296445. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
JeKo-1
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4296445
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why JeKo-1 matters

As of 2026-09-13

JeKo-1 is reviewed as JeKo-1; the current evidence base includes 8 approved drugs, 334 compounds, and 213 assays, with lead potency reaching pChEMBL 8.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 334 compounds, and 213 assays for this target. The dominant activity type is IC50. CHEMBL5641687 is the current potency anchor at pChEMBL 8.9.

Use CHEMBL5641687 as the tractability anchor when discussing potency (pChEMBL 8.9).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 8.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why JeKo-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

334
Total Compounds
213
Total Assays
8
Approved Drugs
IC50: 249.0, EC50: 12.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5641687
 8.9 EC50 —
No preferred name
CHEMBL4170596
 8.9 IC50 —
No preferred name
CHEMBL5647124
 8.8 EC50 —
No preferred name
CHEMBL5647672
 8.8 EC50 —
No preferred name
CHEMBL5646688
 8.8 EC50 —

Approved Drugs

Structure Compound First Approval
IDELALISIB
CHEMBL2216870
 2014
IBRUTINIB
CHEMBL1873475
 2013
VORINOSTAT
CHEMBL98
 2006
DOXORUBICIN
CHEMBL53463
 1974
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T12:56:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296445